Faragli, A.
Merz, S.
Muzio, F. P. Lo
Doeblin, P.
Tanacli, R.
Kolp, C.
Abawi, D.
Ötvös, J.
Stehning, C.
Schnackenburg, B.
Pieske, B.
Post, H.
Klopfleisch, R.
Alogna, A.
Kelle, S.
Funding for this research was provided by:
Deutsches Zentrum für Herz-Kreislaufforschung (81X2100305)
Article History
Received: 30 March 2020
Accepted: 10 May 2020
First Online: 14 May 2020
Compliance with ethical standards
:
: Burkert Pieske reports having received consultancy and lecture honoraria from Bayer Daiichi Sankyo, MSD, Novartis, Sanofi-Aventis, Stealth Peptides and Vifor Pharma; and editor honoraria from the Journal of the American College of Cardiology. Sebastian Kelle reports receiving grants from Philips Healthcare and speaker honoraria from Medis. Patrick Doeblin owns stock of Siemens, Bayer and Fresenius Medical Care. None of the other authors reports a relationship with industry and other relevant entities – financial or otherwise – that might pose a conflict of interest in connection with the submitted article.
: The experimental protocols were approved by the local bioethics committee of Berlin, Germany (G0138/17) and conform to the “European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes” (Council of Europe No 123, Strasbourg 1985).